Management of an Immunocompromised Pediatric Patient With Multiple Hospitalizations for Symptomatic COVID-19 : Journal of Pediatric Hematology/Oncology

Secondary Logo

Journal Logo

Advanced Search
Online Articles: Clinical and Laboratory Observations

Management of an Immunocompromised Pediatric Patient With Multiple Hospitalizations for Symptomatic COVID-19

DeVine, Mackenzie N. PharmD*; Maxwell, Sarah MD, MPH†; Haynes, Andrew S. MD†; MacBrayne, Christine E. PharmD, MSCS*; Boguniewicz, Juri MD†

Author Information

*Department of Pharmacy, Children’s Hospital Colorado

†Department of Pediatrics, Section of Pediatric Infectious Diseases, University of Colorado School of Medicine, Aurora, CO

The authors declare no conflict of interest.

Reprints: Mackenzie N. DeVine, PharmD, Department of Pharmacy, Children’s Hospital Colorado, 13123 E 16th Avenue, P.O. Box 375, Aurora, CO 80045 (e-mail: [email protected]).

Journal of Pediatric Hematology/Oncology 44(1):p e293-e295, January 2022. | DOI: 10.1097/MPH.0000000000002014

Abstract

Relapse of infection due to SARS-CoV-2 has been rarely described and there is little guidance regarding the management of such cases in immunocompromised hosts. We present a case of an adolescent female with B-cell acute lymphoblastic leukemia hospitalized multiple times for symptomatic SARS-CoV-2 infection who was safely treated with 2 courses of remdesivir (RDV) and has had no additional readmissions to date. Though additional studies are needed to confirm the safety and efficacy of an additional course of RDV in the setting of relapsed or prolonged severe COVID-19, our observations suggest that a second course of RDV may be considered.

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid